Factors Associated to the Instability of the INR (International Normalized Ratio ) in the Prevention of Thromboembolism AVK (Anti Vitamin K) in Atrial Fibrillation in the Elderly: Instead of Comorbidities
NCT02841475 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2164
Last updated 2021-09-10
Summary
Atrial fibrillation (AF) is a common condition whose prevalence increases with advancing age . One of the main complications of this arrhythmia is the occurrence of systemic thromboembolism, the first of which the occurrence of cerebrovascular accident (CVA) . The advanced age itself is an independent risk factor for occurrence of stroke in the context of AF , evidenced by the score awarded to the age over 75 years in the risk estimate thromboembolism in the score CHA2DS2-Vasc . Making the elderly a priority target for the prevention of thromboembolism, both because of the increased thromboembolic risk and prevalence of AF in this population. For many years, vitamin K antagonists (VKA) have proven their effectiveness in this context . But the effectiveness and safety of thromboembolism prevention by anti-vitamin K treatment involves maintaining the INR (International Normalized Ratio) in the therapeutic range. Indeed occurred of a thromboembolic or haemorrhagic adverse event directly correlates to having an INR outside the therapeutic range and maintaining the INR in the therapeutic range is subject to many variations inter- and intra-individual. They include, genetic factors , food , drug interactions , as well as disease processes . Or one of the elderly characteristics is the coexistence of multiple pathological processes or comorbidities . The supposed interaction between comorbidities and variability of INR has been little studied: Only a few studies have examined the factors associated with the stability of the INR and unstable . The identification of patients at risk of instability INR yet allow clinicians greater vigilance and better identification of patients for whom the initiation of treatment with vitamin K does not appear the best therapeutic strategy.
Our study seeks to determine whether comorbidity, assessed by the Charlson comorbidity index, are associated with instability of the INR, among more than 80 years for patients treated with AVK atrial fibrillation.
Conditions
Interventions
- OTHER
-
Charlson comorbidity index
Charlson comorbidity index
Sponsors & Collaborators
-
Nantes University Hospital
lead OTHER
Eligibility
- Min Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-09-30
- Primary Completion
- 2013-12-31
- Completion
- 2013-12-31
More Related Trials
-
Weekly Monitoring Strategy of Capillary INR Versus Monthly Monitoring Strategy of Venous INR in Elderly Patients in a Nursing Home.
NCT05561244 ·Status: TERMINATED ·Phase: NA
-
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
NCT02864758 ·Status: COMPLETED
-
Glomerular Filtration Rate-Estimating Equations During Use of Direct Oral Anticoagulants in Elderly Patients
NCT02964546 ·Status: TERMINATED
-
Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage
NCT02091479 ·Status: TERMINATED ·Phase: PHASE3
-
International Normalised Ratio Evaluation by Generalist Practitioners in Full-time Care Establishments for the Elderly
NCT02614573 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis Prevention After Percutaneous Left Atrial Appendage Occlusion
NCT04502017 ·Status: UNKNOWN ·Phase: PHASE4
-
Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin
NCT05150314 ·Status: UNKNOWN
-
Stroke Prophylaxis of AF-patients: Real-life Effectiveness and Safety of Novel Anticoagulants Compared to VKA
NCT02657616 ·Status: COMPLETED
-
Following Patients on Warfarin Therapy to See if Differences in Hemorrhagic Complications Exist
NCT00075985 ·Status: COMPLETED
-
Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty
NCT04878497 ·Status: UNKNOWN
-
Excessive Warfarin Anticoagulation - Causes and Consequences
NCT02761941 ·Status: UNKNOWN
-
Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients
NCT03374540 ·Status: COMPLETED
-
Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-valvular Atrial Fibrillation Treated With Vitamin k Antagonists
NCT02661516 ·Status: COMPLETED
-
Six Years of Follow-up After Idiopathic Venous Throbmoembolism
NCT02884934 ·Status: COMPLETED
-
Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist
NCT02687867 ·Status: COMPLETED
-
Keeping Oral o Parental AnticoaguLation in the Acute Phase of Cardioembolic Ischemic Stroke
NCT05486351 ·Status: UNKNOWN
-
Anticoagulation Preference by AF Patients Study
NCT02607371 ·Status: COMPLETED
-
Comparative Study of Oral Anticoagulation in Left Ventricular Thrombi
NCT03926780 ·Status: COMPLETED ·Phase: PHASE3
-
Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation
NCT00448214 ·Status: COMPLETED ·Phase: PHASE2
-
Warfarin - How Good Are we at Maintaining Target Range ?
NCT01081327 ·Status: COMPLETED
-
Daily Vitamin K in Patients on Warfarin With Unstable INRs
NCT00287313 ·Status: COMPLETED ·Phase: NA
-
Comparative Effectiveness and Safety Between Warfarin and Dabigatran
NCT03254134 ·Status: COMPLETED
-
Balancing of Patients Treated by Vitamin K Antagonists (VKAS) in General Medicine
NCT03914053 ·Status: COMPLETED
-
Anti Vitamin K Therapeutic Education
NCT01587053 ·Status: TERMINATED
-
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation
NCT03642509 ·Status: RECRUITING ·Phase: NA